Home Tools
Log in

Deferoxamine Mesylate

Catalog No. T1637   CAS 138-14-7
Synonyms: desferrioxamine B, Desferrioxamine B mesylate, DFO, DFOM

Deferoxamine Mesylate (DFOM) is an iron-chelating agent that binds free iron in a stable complex. It also is an inhibitor of ferroptosis.

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
Deferoxamine Mesylate Chemical Structure
Deferoxamine Mesylate, CAS 138-14-7
Pack Size Availability Price/USD Quantity
100 mg In stock $ 50.00
1 mL * 10 mM (in DMSO) In stock $ 64.00
Bulk Inquiry
Get quote
Select Batch  
Purity: 99.8%
Purity: 99.65%
Purity: 99.45%
Purity: 99.18%
Purity: 99.13%
Purity: 99.13%
Purity: 99.04%
Purity: 98.52%
Purity: 98.34%
Purity: 98%
Purity: 94.68%
Contact us for more batch information
Biological Description
Chemical Properties
Storage & Solubility Information
Description Deferoxamine Mesylate (DFOM) is an iron-chelating agent that binds free iron in a stable complex. It also is an inhibitor of ferroptosis.
In vitro Deferoxamine (DFO) had growth-arresting and apoptosis-inducing effect on TAMSCs and bone marrow MSCs (BMMSCs). DFO also influenced the expression pattern of adhesion molecule VCAM-1 on both TAMSCs and BMMSCs [1]. LLC-PK(1) cells were exposed to hypoxia, stimulated with desferrioxamine (Deferoxamine). Although all stimuli elicited HIF-1alpha stabilization with differences in the time-dependent accumulation pattern, significant variations appeared with regard to signaling [2]. No significant differences could be seen between AdMSC seeded collagen-GAG that was exposed to 1% O2 and 120?μM DFO. Cells exposed to 30 or 60?μM of DFO showed lower expression of HIF-1α [3].
In vivo The rats were treated with deferoxamine (DFX) or vehicle (100mg/kg) for a maximum of 7 days. In SAH rat, the peak time of brain edema and BBB impairment in the cortex was at day 3 after SAH. SAH resulted in a significant increase in ferritin expression in the cortex. The ferritin positive cells were colocalized with endothelial cells, pericytes, astrocytes, microglia, and neurons [4]. Mice were treated 3x/week with 0.24 C intranasal (IN) DFO for 18 weeks from 36 to 54 weeks of age. IN DFO treatment significantly decreased loss of both reference and working memory in the Morris and radial arm water mazes, and also decreased soluble Aβ40 and Aβ42 in cortex and hippocampus. Further, IN DFO decreased activity of GSK3β, and led to decreases in oxidative stress [5].
Cell Research After cells were seeded onto the collagen-GAG discs and allowed to adhere for 3?hours, they were placed into a hypoxic incubator with 1% O2 or incubated under standard cell culture conditions with deferoxamine mesylate (DFO) added to final concentrations of 30, 60, or 120?μM. Scaffolds seeded with AdMSCs cultured under standard conditions were used as a control [3].
Animal Research The animals were divided into 4 groups: sham, SAH, SAH+vehicle and SAH+DFX (100mg/kg) group. DFX was administered intraperitoneally 2 and 6 hours after hemorrhage followed by every 12 hours for a maximum of 7 days. The same time course and dosage of saline were administered in the SAH+vehicle group. Afterward, rats underwent behavioral testing and were euthanized at day 1, 3, 7 and 28 for brain water content calculation, immunohistochemistry or western blot assays. The study was performed in three parts. Part 1 measured the brain water content, Evan's blue extravasation, and ultrastructural abnormalities at day 1, 3 and 7 after SAH to evaluate the time-dependent changes in brain edema and BBB disruption (n = 4 per time point and group). Part 2 investigated the role of iron in SAH-induced BBB disruption at day 1, 3 and 7 by brain water content (n = 4, per time point and group), Evan's blue extravasation (n = 4, per time point and group), transmission electron microscopy (n = 4, per time point and group), immunohistochemistry (n = 4, per time point and group) and western blot analysis (n = 3, per time point and group). Part 3 compared the acute (n = 61, per group at day 1; n = 42, per group at day 3; n = 23, per group at day 7) and long term (n = 4, per group at day 28) neurological function after SAH in each group to determine the effect of iron chelation on SAH-induced neurologic impairment [4].
Synonyms desferrioxamine B, Desferrioxamine B mesylate, DFO, DFOM
Molecular Weight 656.79
Formula C26H52N6O11S
CAS No. 138-14-7


store at low temperature,keep away from direct sunlight

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Solubility Information

DMSO: 152.3 mM

H2O: 20.83 mg/mL (31.72 mM)

TargetMolReferences and Literature

1. Wang G, et al. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64. 2. Sandau KB, et al. Regulation of the hypoxia-inducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. J Biol Chem. 2001 Oct 26;276(43):39805-11. 3. Wahl EA, et al. VEGF released by deferoxamine preconditioned mesenchymal stem cells seeded on collagen-GAG substrates enhances neovascularization. Sci Rep. 2016 Nov 10;6:36879. 4. Li Y, et al. Effects of deferoxamine on blood-brain barrier disruption after subarachnoid hemorrhage. PLoS One. 2017 Mar 1;12(3):e0172784. 5. Fine JM, et al. Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation. Neurosci Lett. 2015 Jan 1;584:362-7. 6. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e 8. Sang M, Luo R, Bai Y, et al. BHQ-Cyanine-Based “Off–On” Long-Circulating Assembly as a Ferroptosis Amplifier for Cancer Treatment: A Lipid-Peroxidation Burst Device[J]. ACS applied materials & interfaces. 2019, 11(46): 42873-42884. 9. Sang M, Luo R, Bai Y, et al. BHQ-Cyanine Based “Off-On” Long-Circulating Assembly as Ferroptosis Amplifier for Cancer Treatment: a Lipid-Peroxidation Burst Device[J]. ACS applied materials & interfaces. 2019. 10. Wang S, Li F, Qiao R, et al. Arginine-Rich Manganese Silicate Nanobubbles as a Ferroptosis-Inducing Agent for Tumor-Targeted Theranostics[J]. ACS nano. 2018 Dec 26;12(12):12380-12392.


1. Bi G, Liang J, Shan G, et al.Retinol saturase mediates retinoid metabolism to impair a ferroptosis defense system in cancer cells.Cancer Research.2023: CAN-22-3977. 2. Zhu X, Huang N, Ji Y, et al.Brusatol induces ferroptosis in oesophageal squamous cell carcinoma by repressing GSH synthesis and increasing the labile iron pool via inhibition of the NRF2 pathway.Biomedicine & Pharmacotherapy.2023, 167: 115567. 3. Chen T, Leng J, Tan J, et al.Discovery of Novel Potent Covalent Glutathione Peroxidase 4 Inhibitors as Highly Selective Ferroptosis Inducers for the Treatment of Triple-Negative Breast Cancer.Journal of Medicinal Chemistry.2023 4. Zhao G, Liang J, Shan G, et al.KLF11 regulates lung adenocarcinoma ferroptosis and chemosensitivity by suppressing GPX4.Communications Biology.2023, 6(1): 570. 5. Liu J, Pan Z, Tong B, et al.Artesunate protects against ocular fibrosis by suppressing fibroblast activation and inducing mitochondria‐dependent ferroptosis.The FASEB Journal.2023, 37(6): e22954. 6. Li Y, Bao Y, Li Y, et al.RSL3 Inhibits Porcine Epidemic Diarrhea Virus Replication by Activating Ferroptosis.Viruses.2023, 15(10): 2080. 7. Gao X, Jiang P, Wei X, et al.Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity.BMC cancer.2023, 23(1): 1-16. 8. Besskaya V, Zhang H, Bian Y, et al.Hepatic nuclear factor 4 alpha promotes the ferroptosis of lung adenocarcinoma via transcriptional activation of cytochrome P450 oxidoreductase.PeerJ.2023, 11: e15377. 9. Zhou Y, Wu H, Wang F, et al. GPX7 Is Targeted by miR-29b and GPX7 Knockdown Enhances Ferroptosis Induced by Erastin in Glioma. Frontiers in oncology. 2021, 11: 802124-802124. 10. Bi G, Liang J, Zhao M, et al. MiR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma by targeting CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways. Molecular Therapy-Nucleic Acids. 2022
11. Huang C Y, Chen L J, Chen G, et al. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2022, 23(19): 11092. 12. Sang M, Luo R, Bai Y, et al. BHQ-Cyanine-Based “Off–On” Long-Circulating Assembly as a Ferroptosis Amplifier for Cancer Treatment: A Lipid-Peroxidation Burst Device. ACS applied materials & interfaces. 2019, 11(46): 42873-42884. 13. Wang S, Li F, Qiao R, et al. Arginine-Rich Manganese Silicate Nanobubbles as a Ferroptosis-Inducing Agent for Tumor-Targeted Theranostics. ACS nano. 2018 Dec 26;12(12):12380-12392. 14. Fang Y, Tan Q, Zhou H, et al. Discovery and optimization of 2-(trifluoromethyl) benzimidazole derivatives as novel ferroptosis inducers in vitro and in vivo. European Journal of Medicinal Chemistry. 2022: 114905. 15. Lv Q, Niu H, Yue L, et al. Abnormal Ferroptosis in Myelodysplastic Syndrome. Frontiers in Oncology. 2020 Sep 2;10:1656 16. Deng F, Xu G, Cheng Z, et al. Hepatitis B Surface Antigen Suppresses the Activation of Nuclear Factor Kappa B Pathway via Interaction With the TAK1-TAB2 Complex. Frontiers in Immunology. 2021, 12: 233. 17. Liu Y, Li H, Luo Z, et al. Artesunate, a new antimalarial clinical drug, exhibits potent anti‐AML activity by targeting the ROS/Bim and TFRC/Fe2+ pathways. British Journal of Pharmacology. 2022 18. Sang M, Luo R, Bai Y, et al. Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer. Theranostics. 2019, 9(21): 6209. 19. Wu W Y, Wang Z X, Li T S, et al. SSBP1 drives high fructose-induced glomerular podocyte ferroptosis via activating DNA-PK/p53 pathway. Redox Biology. 2022: 102303. 20. Ouyang S, Li H, Lou L, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biology. 2022: 102317 21. Li X, Wang H, Lu Z, et al. Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents. Journal of Medicinal Chemistry. 2016 Sep 22;59(18):8326-44 22. Cheng Y, Qu W, Li J, et al. Ferristatin II, an Iron Uptake Inhibitor, Exerts Neuroprotection against Traumatic Brain Injury via Suppressing Ferroptosis. ACS Chemical Neuroscience. 2022 23. Shan G, Bi G, Zhao G, et al.Inhibition of PKA/CREB1 pathway confers sensitivity to ferroptosis in non-small cell lung cancer.Respiratory Research.2023, 24(1): 1-15. 24. Liu S, Tao Y, Wu S, et al.Sanguinarine chloride induces ferroptosis by regulating ROS/BACH1/HMOX1 signaling pathway in prostate cancer.Chinese Medicine.2024, 19(1): 1-18. 25. Ying Z, Yin M, Zhu Z, et al.Iron Stress Affects the Growth and Differentiation of Toxoplasma gondii.International Journal of Molecular Sciences.2024, 25(5): 2493.

Related compound libraries

This product is contained In the following compound libraries:
Anti-Cancer Approved Drug Library Anti-Cancer Clinical Compound Library Anti-Cancer Drug Library Anti-COVID-19 Compound Library Anti-Aging Compound Library Cuproptosis Compound Library FDA-Approved Drug Library Cell Cycle Compound Library Anti-Neurodegenerative Disease Compound Library Bioactive Compounds Library Max

Related Products

Related compounds with same targets
HIF-1α-IN-2 hydrochloride HIV-IN-7 HIF-2α-IN-9 PHD2-IN-1 VHL-IN-1 PHD-IN-1 PHD-IN-2 HIF-1α-IN-6

TargetMolDose Conversion

You can also refer to dose conversion for different animals. More

TargetMol In vivo Formulation Calculator (Clear solution)

Step One: Enter information below
Average weight of animals
Dosing volume per animal
Number of animals
Step Two: Enter the in vivo formulation
% Tween 80
% ddH2O
Calculate Reset


Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator

Molarity Calculator allows you to calculate the

  • Mass of a compound required to prepare a solution of known volume and concentration
  • Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Concentration of a solution resulting from a known mass of compound in a specific volume
See Example

An example of a molarity calculation using the molarity calculator
What is the mass of compound required to make a 10 mM stock solution in 10 ml of water given that the molecular weight of the compound is 197.13 g/mol?
Enter 197.13 into the Molecular Weight (MW) box
Enter 10 into the Concentration box and select the correct unit (millimolar)
Enter 10 into the Volume box and select the correct unit (milliliter)
Press calculate
The answer of 19.713 mg appears in the Mass box


Calculator the dilution required to prepare a stock solution

Calculate the dilution required to prepare a stock solution
The dilution calculator is a useful tool which allows you to calculate how to dilute a stock solution of known concentration. Enter C1, C2 & V2 to calculate V1.

See Example

An example of a dilution calculation using the Tocris dilution calculator
What volume of a given 10 mM stock solution is required to make 20ml of a 50 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=50 μM, V2=20 ml and V1 is the unknown:
Enter 10 into the Concentration (start) box and select the correct unit (millimolar)
Enter 50 into the Concentration (final) box and select the correct unit (micromolar)
Enter 20 into the Volume (final) box and select the correct unit (milliliter)
Press calculate
The answer of 100 microliter (0.1 ml) appears in the Volume (start) box


Calculate the volume of solvent required to reconstitute your vial.

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial.
Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Enter the chemical formula of a compound to calculate its molar mass and elemental composition

Tip: Chemical formula is case sensitive: C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed n the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.


Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.


Deferoxamine Mesylate 138-14-7 Apoptosis Autophagy Chromatin/Epigenetic Metabolism Neuroscience Others HIF/HIF Prolyl-Hydroxylase Ferroptosis Mitophagy Beta Amyloid HIFs neovascularization TAMSCs desferrioxamine B diabetes mellitus Akt PKB Protein kinase B SH-SY5Y Hypoxia-inducible factors Deferoxamine Desferrioxamine B mesylate DFO Desferrioxamine B Mesylate Inhibitor MEFs cancer Alzheimer’s disease HIF-PH Reactive Oxygen Species BMMSCs inhibit DFOM COVID-19 inhibitor